Delaware-based pharma company Incyte has secured priority review for pemigatinib from the US Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic cholangiocarcinoma. The priority review for pemigatinib is for the treatment of the condition in previously treated patients having FGFR2 fusions or rearrangements. Cholangiocarcinoma is a rare cancer that occurs […]
Innovent Biologics, a leading Chinese biopharma company, has struck a landmark deal with Incyte, a prominent US pharmaceutical firm, to develop and commercialize three investigational cancer drugs. The agreement, valued at up to $391.5 million, covers pemigatinib, a FGFR1/2/3 inhibitor; itacitinib, a JAK1 inhibitor; and parsaclisib, a PI3Kδ inhibitor, which are currently in clinical stages. […]